ACKR3 and cancer: While AMD3100 is highly effective at blocking CXCR4, it has also shown affinity for CXCR7, and can be cardiotoxic when used as a long-term treatment in HIV patients; however, AMD3100 has been approved by the FDA and EMA as a treatment for other pathologies and could also be approved as a cancer therapy in the future [238].